Evidence map›Paper›PMID 33811589›Full record

ArticleCellular and molecular neurobiology2022

A High-Fat Diet Increases Activation of the Glucagon-Like Peptide-1-Producing Neurons in the Nucleus Tractus Solitarii: an Effect that is Partially Reversed by Drugs Normalizing Glycemia.

Grazyna Lietzau, Stelia Ntika, Hiranya Pintana, Linda Tracy, Thomas Klein, Thomas Nyström, Vladimer Darsalia, Cesare Patrone, Camilla Krizhanovskii

Open access · hybridAbstract read
In one paragraph

Article in Cellular and molecular neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Grazyna LietzauDepartment of Clinical Science and Education, Karolinska Institutet, Sodersjukhuset Internal Medicine, 118 83, Stockholm, Sweden. grazyna.lietzau@gumed.edu.pl.ORCID http://orcid.org/0000-0001-5119-3082
Stelia NtikaDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Hiranya PintanaDepartment of Clinical Science and Education, Karolinska Institutet, Sodersjukhuset Internal Medicine, 118 83, Stockholm, Sweden.
Linda TracyDepartment of Research, Södertälje Hospital, Södertälje, Sweden.
Thomas KleinBoehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Thomas NyströmDepartment of Clinical Science and Education, Karolinska Institutet, Sodersjukhuset Internal Medicine, 118 83, Stockholm, Sweden.
Vladimer DarsaliaDepartment of Clinical Science and Education, Karolinska Institutet, Sodersjukhuset Internal Medicine, 118 83, Stockholm, Sweden.
Cesare PatroneDepartment of Clinical Science and Education, Karolinska Institutet, Sodersjukhuset Internal Medicine, 118 83, Stockholm, Sweden.
Camilla KrizhanovskiiDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. camilla.krizhanovskii@ki.se.ORCID http://orcid.org/0000-0003-2195-165X
Karolinska Institutet · SEBoehringer Ingelheim (Germany) · DESödertälje Sjukhus · SE

Funding

Hjärt-Lungfonden 20160511
6 · The paper itself

Abstract

Glucagon-like peptide-1 (GLP-1) is a peripheral incretin and centrally active peptide produced in the intestine and nucleus tractus solitarii (NTS), respectively. GLP-1 not only regulates metabolism but also improves cognition and is neuroprotective. While intestinal GLP-1-producing cells have been well characterized, less is known about GLP-1-producing neurons in NTS. We hypothesized that obesity-induced type 2 diabetes (T2D) impairs the function of NTS GLP-1-producing neurons and glycemia normalization counteracts this effect. We used immunohistochemistry/quantitative microscopy to investigate the number, potential atrophy, and activation (cFos-expression based) of NTS GLP-1-producing neurons, in non-diabetic versus obese/T2D mice (after 12 months of high-fat diet). NTS neuroinflammation was also assessed. The same parameters were quantified in obese/T2D mice treated from month 9 to 12 with two unrelated anti-hyperglycemic drugs: the dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride. We show no effect of T2D on the number and volume but increased activation of NTS GLP-1-producing neurons. This effect was partially normalized by both anti-diabetic treatments, concurrent with decreased neuroinflammation. Increased activation of NTS GLP-1-producing neurons could represent an aberrant metabolic demand in T2D/obesity, attenuated by glycemia normalization. Whether this effect represents a pathophysiological process preceding GLP-1 signaling impairment in the CNS, remains to be investigated.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like Peptide 1AnimalsBlood GlucoseDiet, High-FatMiceNeuronsObesitySolitary NucleusBlood GlucoseGlucagon-Like Peptide 1DiabetesDipeptidyl peptidase-4 inhibitorsGLP-1Nucleus tractus solitariiObesitySulfonylurea

Identifiers

PMID33811589
PMCPMC9239971
OpenAlexW3146059118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.